Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P588: Switching from infliximab originator to a first biosimilar is safe and effective: A single-centre series with through levels and anti-drug antibodies determinationECCO '18 Vienna
Year: 2018
Authors:

M. Daperno*, C. Guiotto, A. Italia, A. Lavagna, A. Negri, E. Ercole, M. Cosimato, C. Rigazio, R. Rocca

Mauriziano Hospital, Gastroenterology Unit, Torino, Italy

P589: Adherence to medical treatment in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

S. Jardak1*, L. Hamzaoui1,2,3, K. Agar2, M. Medhioub2, A. Khsiba2, M.M. Azouz2

1Nabeul-Tunisia, Department of Gastroenterology Nabeul-Tunisia, Nabeul, Tunisia, 2Nabeul-Tunisia, Nabeul-Tunisia, Nabeul, Tunisia, 3Mohamed Taher Maamouri Hospital, Department of Gastroenterology, Nabeul, Tunisia

P590: Laparoscopy in Crohn’s disease: Learning curve and current practiceECCO '18 Vienna
Year: 2018
Authors:

D. Mege1,2*, F. Michelassi1

1New York Presbyterian Hospital, New York, USA, 2Aix-Marseille University, Marseille, France

P591: Gastroenterologist performed point-of-care gastrointestinal ultrasound improves patient understanding of disease activity, symptomatology, management decisions and clinical outcomesECCO '18 Vienna
Year: 2018
Authors:

A. Friedman1*, A. Asthana1,2, S. Knowles3, A. Robbins4, P. Gibson1

1The Alfred Centre, Department of Gastroenterology, Monash University, Melbourne, Australia, 2The Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia, 3Swinburne University, Psychological Sciences and Statistics, Hawthorn, Australia, 4AbbVie Pty Ltd., Immunology (Medical), Sydney, Australia

P592: Efficacy of vedolizumab for induction and maintenance of clinical remission in ulcerative colitis: The UCLH experienceECCO '18 Vienna
Year: 2018
Authors:

M. Vinayaga-Pavan*, T. Kumagai, I. Parisi, J. Barragry, R. Sundramoorthi, L. Whitley, H. Parker, R. Kettle, N. McCabrey, E. Steward, S. McCartney, S. Bloom, R. Vega, S. Mehta, F. Rahman

University College London Hospital, Department of Gastroenterology, London, UK

P593: Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre studyECCO '18 Vienna
Year: 2018
Authors:

C. Briot1*, P. Faure2, A.L. Parmentier1, C. Gay1, C. Trang3, M. Nachury4, S. Viennot5, R. Altwegg6, P. Bulois7, L. Thomassin8, M. Serrero9, P. Ah Soune10, C. Gilletta11, L. Plastaras12, M. Simon13, X. Dray14, L. Caillo15, E. Del Tedeco16, V. Abitbol17, C. Zallot18, T. Degand19, V. Rossi20, G. Bonnaud21, D. Colin22, B. Morel23, J.B. Danset24, B. Winkfield25, J. Filippi26, A. Amiot27, A. Attar28, A. Bourreille29, J.C. Grimaud9, A. Blain30, L. Peyrin Biroulet18, L. Vuitton1

1University Hospital Center Jean Minjoz, Gastroenterology, Besancon, France, 2Private Clinic Pasteur, Gastroenterology, Toulouse, France, 3University Hospital Center, Gastroenterology, Nantes, France, 4University Hospital Center, Gastroenterology, Lille, France, 5University Hospital Center, Gastroenterology, Caen, France, 6Private Practise, Gastroenterology, Montpellier, France, 7Private Clinic La Louviere, Gastroenterology, Lille, France, 8University Hospital Center, Gastroenterology, Rouen, France, 9Aphm North Hospital, Gastroenterology, Marseille, France, 10Private Practice, Gastroenterology, Toulon, France, 11University Hospital Center Rangueil, Gastroenterology, Toulouse, France, 12Hospital Louis Pasteur, Gastroenterology, Colmar, France, 13Hospital Saint Louis APHP, Gastroenterology, Paris, France, 14Hospital Saint Antoine APHP, Gastroenterology, Paris, France, 15University Hospital Center Caremeau, Gastroenterology, Nimes, France, 16University Hospital Center, Gastroenterology, Saint Etienne, France, 17University Hospital Center Cochin APHP, Gastroenterology, Paris, France, 18University Hospital Center Brabois, Gastroenterology, Nancy, France, 19University Hospital Center Le Bocage, Gastroenterology, Dijon, France, 20Hospital Haut Anjou, Gastroenterology, Chateau Gontier, France, 21Private Clinic Des cèdres, Gastroenterology, Cornebarrieu, France, 22Private Practice, Gastroenterology, Belfort, France, 23Private Hospital, Gastroenterology, Saint Priest en Jarez, France, 24European Hospital Georges Pompidou APHP, Gastroenterology, Paris, France, 25Hospital HNFC, Gastroenterology, Trevenans, France, 26University Hospital Center Larchet, Gastroenterology, Nice, France, 27University Hospital Henri Mondor APHP, Gastroenterology, Créteil, France, 28Private Practice, Gastroenterology, Paris, France, 29University Hospital Center Hôtel Dieu, Gastroenterology, Nantes, France, 30Institut Mutualiste Montsouris, Gastroenterology, Paris, France

P594: Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn’s disease (CD)ECCO '18 Vienna
Year: 2018
Authors:

J. Panés1*, D. García-Olmo2, A. Parfionovas3, C. Agboton4, J.M. Khalid5

1Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Gastroenterology Department, Barcelona, Spain, 2Faculty of Medicine, Autonomous University of Madrid, Department of Surgery, Madrid, Spain, 3Takeda Pharmaceuticals International Co., Cambridge, USA, 4Takeda Pharmaceuticals International AG, Zurich, Switzerland, 5Takeda Development Centre, London, UK

P595: Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD–GO-SWIBREGECCO '18 Vienna
Year: 2018
Authors:

C. Eriksson1, D. Bergemalm1*, L. Vigren2, L. Nilsson3, I. Visuri1, H. Hjortswang4, R. Udumyan5, S. Almer6, M. Seddighzadeh7, E. Hertervig8, P. Karlén3, H. Strid9, J. Halfvarson1, The GO-SWIBREG study group

1Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, 2Hospital of Trelleborg, Department of Medicine, Division of Gastroenterology, Trelleborg, Sweden, 3Danderyd Hospital, Department of Internal Medicine, Stockholm, Sweden, 4Linköping University, Department of Gastroenterology and Department of Clinical and Experimental Medicine, Linköping, Sweden, 5Örebro University, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health, Örebro, Sweden, 6Karolinska Institute, Department of Medicine, Gastrocentrum, Stockholm, Sweden, 7Merck Sharp and Dohme, Sweden, Stockholm, Sweden, 8Skåne University Hospital, Department of Gastroenterology, Lund, Sweden, 9Södra Älvsborgs Hospital, Department of Internal Medicine, Borås, Sweden

P596: Clinical utility of vedolizumab trough levels and anti-drug antibodies in the management of IBDECCO '18 Vienna
Year: 2018
Authors:

D. Jelk1, M. Perreau2, P. Michetti3, M. Maillard2*

1Lausanne University, Lausanne, Switzerland, 2CHUV – Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 3Crohn's and Colitis Center, Lausanne, Switzerland

P597: Effectiveness and safety of vedolizumab therapy in an ulcerative colitis cohort with significant prior anti-TNF exposureECCO '18 Vienna
Year: 2018
Authors:

C. Judge1,2*, N. McGettigan2,3, T. Ryan2,4, K. Hazel2,5, P. Singh2,6, V. Parihar2,6, R. Stack2,7, A. O'Connor2,8, C. Dunne1,2, G. Cullen2,4, L. Egan2,3, G. Harewood2,7, F. MacCarthy1,2, S. McKiernan1,2, H. Mulcahy2,4, F. Murray2,7, S. Patchett2,7, J. Sheridan2,4, D. Trevian2,7, N. Breslin2,8, R. Farrell2,5, J. Keohane2,6, O. Kelly2,5, D. McNamara2,8, B. Ryan2,8, C. Smyth2,5, C. O'Morain2,9, S. Sengupta2,6, E. Slattery2,3, G. Doherty2,4, D. Kevans1,2, A. O'Toole2,7

1St James's Hospital, Department of Gastroenterology, Dublin, Ireland, 2INITIative, Investigator Network for Inflammatory Bowel Disease Therapy in Ireland, Dublin, Ireland, 3Galway University Hospital, Department of Gastroenterology, Galway, Ireland, 4St Vincent's University Hospital, Department of Gastroenterology and Centre for Colorectal Disease, Dublin, Ireland, 5Connolly Hospital Blanchardstown, Department of Gastroenterology, Dublin, Ireland, 6Our Lady of Lourdes Hospital, Department of Gastroenterology, Drogheda, Ireland, 7Beaumont Hospital, Department of Gastroenterology, Dublin, Ireland, 8Tallaght hospital, Department of Gastroenterology, Dublin, Ireland, 9Beacon Hospital, Department of Gastroenterology, Dublin, Ireland

P598: Adherence to treatment in IBD: to see beyond motivationECCO '18 Vienna
Year: 2018
Authors:

J. Poza Cordon1*, C. Suarez Ferrer2,3, O. Crivillen Anguita3, E. Martin Arranz1, M. Jaquotot Herranz1, S. Gomez Senent1, M.D. Martin Arranz1

1Hospital Universitario La Paz, Department of Gastroenterology, Madrid, Spain, 2Hospital Universitario la paz, Radiology, Madrid, Spain, 3Hospital Universitario la paz, Gastroenterology, Madrid, Spain

P599: Short- and long-term outcome of minimally invasive approach for Crohn’s disease: Comparison between single incision, robotic-assisted and conventional laparoscopyECCO '18 Vienna
Year: 2018
Authors:

D. Zambonin1*, F. Giudici1, F. Ficari1, F. Rogai2, S. Scaringi3

1University of Florence, Florence, Italy, 2Division of Gastroenterology, AOU Careggi Hospital, Department of Emergency, Florence, Italy, 3Digestive Surgery Unit, Careggi University Hospital, Department of Surgery and Translational Medicine, Florence, Italy

P600: Clinical utility of anti-IFI16 seroreactivity in the response to anti-TNF therapy in IBDECCO '18 Vienna
Year: 2018
Authors:

V. Caneparo1,2, B. Verstockt3,4, S. Vermeire3,4, S. Landolfo1, M. Gariglio2, M. De Andrea1,2*

1University of Turin, Medical School, Department of Public Health and Pediatric Sciences, Viral Pathogenesis Unit, Turin, Italy, 2University of Piemonte Orientale, Department of Translational Medicine, Virology Unit, Novara, Italy, 3University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 4Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

P601: Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST studyECCO '18 Vienna
Year: 2018
Authors:

R. Panaccione1*, R. Atreya2, M. Ferrante3, M.C. Dubinsky4, B.E. Sands4, M.T. Abreu5, F. Cataldi6, J.V. Enejosa6, Q. Zhou6, B. Huang6, A.P. Lacerda6, A.L. Pangan6

1University of Calgary, Calgary, Canada, 2Friedrich-Alexander-University Erlangen-Nürnberg, Medical Clinic 1, Erlangen, Germany, 3University Hospitals Leuven, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai, New York, USA, 5University of Miami, Miami, USA, 6AbbVie Inc., North Chicago, USA

P602: Factors associated with discontinuation of initial and subsequent tumour necrosis factor inhibitors in a large paediatric inflammatory bowel disease observational cohortECCO '18 Vienna
Year: 2018
Authors:

J. Kaplan1,2*, C. Liu3, E. King3, J. Bass4, A. Patel5, G. Tomer6, J. Tung7, J. Pratt3, S. Chen3, T. Lissoos8, R. Colletti9, ImproveCareNow Network

1MassGeneral Hospital for Children, Pediatric Gastroenterology, Boston, USA, 2Harvard Medical School, Boston, USA, 3Cincinnati Children's Hospital, Cincinnati, USA, 4Children’s Mercy Hospital, Kansas City, USA, 5University of Texas-Southwestern/Children's Medical Center, Dallas, USA, 6The Children’s Hospital at Montefiore, Bronx, USA, 7Mayo Clinic-Children’s Center, Rochester, USA, 8Takeda Pharmaceuticals USA, Deerfield, USA, 9University of Vermont College of Medicine, Burlington, USA

P603: Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

J. Hanžel1*, N. Sever1, I. Ferkolj1, B. Štabuc1, N. Smrekar1, M. Koželj1, G. Novak1, A. Gils2, D. Drobne1

1University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia, 2KU Leuven, Laboratory of Pharmaceutical Biology, Leuven, Belgium

P604: Interest in the addition of azathioprine (AZA) to the switch of anti-TNF in IBD patients in loss of response with undetectable anti-TNF trough levels and anti-drug antibodies: A prospective randomised trialECCO '18 Vienna
Year: 2018
Authors:

X. Roblin1*, S. Paul2, G. Boschetti3, J.M. Phelip4, E. Del Tedesco4, A. Berger5, S. Nancey3, N. Williet6, B. Flourie3

1Gastroneterology Unit, Saint Etienne, France, 2University of Saint Etienne, Immunology, Saint Etienne, France, 3University of Lyon, Lyon, France, 4University Hospital, Gastroenterology, Saint Etienne, France, 5Saint Etienne University, Saint Etienne, France, 6CHU Saint Etienne, Saint Etienne, France

P605: Transanal minimally invasive proctectomy (TaMIP) in patients with Crohn’s disease: A cohort study from the TaTME international databaseECCO '18 Vienna
Year: 2018
Authors:

G. Pellino1,2*, K. Sahnan2,3, M. Penna3,4, S. Adegbola2,3, P. Chandrasinghe2,3,5, R. Hompes4, A. Spinelli6,7, J. Warusavitarne2,3, on behalf of the International TaTME Registry Collaborative

1Università della Campania, Unit of Colorectal Surgery, Naples, Italy, 2St Mark's Hospital, Fistula Research Unit, London, UK, 3Imperial College, Department of Surgery and Cancer, London, UK, 4Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, UK, 5Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka, 6Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy, 7Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy

P606: Health-related utility weights in Crohn's disease patients with perianal fistulaECCO '18 Vienna
Year: 2018
Authors:

L. Longworth1*, D. Fountain1, J. Singh1, I. Azzabi2, G. Owen3

1PHMR Ltd., London, UK, 2Takeda Pharmaceuticals International GmbH, Zurich, Switzerland, 3Takeda UK Ltd., High Wycombe, UK

P607: Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patientsECCO '18 Vienna
Year: 2018
Authors:

S. Fischer1*, E. Klenske1, H. Schmitt1, F. Vitali1, S. Hirschmann1, F. Koch1, A. Ramming2, S. Zundler1, D. Nagore3, W. Uter4, M.F. Neurath1, R. Atreya1

1Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany, 2Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine 3, Erlangen, Germany, 3Progentica Biopharma, Derio, Spain, 4Friedrich-Alexander University Erlangen-Nürnberg, Department of Medical Informatics, Biometry and Epidemiology, Erlangen, Germany